- Perrigo launches generic equivalent to prescription-only Vanos Cream 0.1%
- Perrigo recalls APAP infant suspension liquid due to the possibility of missing dose markings on the dosing syringe
- Diplomat Pharmacy recognized by Michigan governor during State of the State address
- Irish High Court approves Perrigo-Elan deal
- Diplomat's Jennifer Hagerman named president-elect of Michigan Pharmacists Association for 2014
ALLEGAN, Mich. — The Food and Drug Administration has approved a drug from Perrigo and Cobrek Pharmaceuticals for treating scalp conditions.
Perrigo said that Cobrek, with which it is partnering, had received approval for betamethasone validate foam in the 0.12% strength. The drug is a generic version of Luxiq foam, made by GlaxoSmithKline subsidiary Stiefel Labs, and is used to treat corticosteroid-responsive skin conditions of the scalp, also known as scalp psoriasis.
The branded version of the drug has annual sales of about $40 million, according to Perrigo.